Page last updated: 2024-12-06

cetiedil

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Cetiedil is a vasodilator and platelet aggregation inhibitor that was developed in the 1970s for the treatment of peripheral vascular disease. Its mechanism of action is thought to involve inhibition of phosphodiesterase activity, leading to increased intracellular cAMP levels and relaxation of smooth muscle cells. Cetiedil has been studied for its potential therapeutic effects in a variety of conditions, including Raynaud's phenomenon, intermittent claudication, and migraine headaches. However, its clinical use has been limited by its side effects, which include nausea, vomiting, and headache. It is no longer widely used due to the development of more effective and safer treatments for these conditions.'

cetiedil: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID66384
CHEMBL ID419380
CHEBI ID34619
SCHEMBL ID458084
MeSH IDM0049814

Synonyms (27)

Synonym
cetiedil
NCI60_021536
2-(hexahydro-1h-azepin-1-yl)ethyl-alpha-cyclohexyl-3-thiopheneacetic acid
einecs 238-028-2
brn 1591408
cetiedilum [inn-latin]
2-(1-azepanyl)ethyl 2-cyclohexyl-2-(3-thienyl)acetat
fusten
3-thiopheneacetic acid, alpha-cyclohexyl-, 2-(hexahydro-1h-azepin-1-yl)ethyl ester
cetiedil [inn]
alpha-cyclohexyl-3-thiopheneacetic acid, 2-(hexahydro-1h-azepin-1-yl)ethyl ester
14176-10-4
2-(azepan-1-yl)ethyl 2-cyclohexyl-2-thiophen-3-ylacetate
chebi:34619 ,
CHEMBL419380
unii-621rt200to
621rt200to ,
cetiedilum
cetiedil [mi]
3-thiopheneacetic acid, .alpha.-cyclohexyl-, 2-(hexahydro-1h-azepin-1-yl)ethyl ester
2-(hexahydro-1h-azepin-1-yl)ethyl .alpha.-cyclohexyl-3-thiopheneacetate
cetiedil [who-dd]
SCHEMBL458084
2-(azepan-1-yl)ethyl 2-cyclohexyl-2-(3-thienyl)acetate
Q5065661
DB13753
DTXSID70864474

Research Excerpts

Overview

Cetiedil is a potential antisickling agent whose major effect appears to be at the erythrocyte membrane. It is a potent blocker of acetylcholine and choline fluxes.

ExcerptReferenceRelevance
"Cetiedil is a potential antisickling agent whose major effect appears to be at the erythrocyte membrane. "( Effect of cetiedil on cation and water movements in erythrocytes.
Asakura, T; Schmidt, WF; Schwartz, E, 1982
)
2.11
"Cetiedil is a potent blocker of acetylcholine and choline fluxes. "( Effect of cetiedil analogs on acetylcholine and choline fluxes in synaptosomes and vesicles.
Diebler, MF; Gaudry-Talarmain, YM; Israƫl, M; Lancelot, JC; Lesbats, B; Robba, M, 1989
)
2.12
"Cetiedil citrate is an antisickling agent shown to be effective in reducing the severity and duration of acute sickle cell crisis. "( A single-dose pharmacokinetic study of the antisickling agent cetiedil.
Berkowitz, LR; Cross, RE; Ng, KT; Orringer, EP; Phillips, JC; Powell, JR; Reed, J; Rogers, JF; Wojcieszyn, O, 1986
)
1.95

Effects

Cetiedil has been reported to relieve painful crises in sickle cell anemia and to have antisickling properties in vitro. It causes a rise in passive Na+ movements and inhibits a specific increase in K+ permeability.

ExcerptReferenceRelevance
"Cetiedil has two such effects: It causes a rise in passive Na+ movements and it inhibits a specific increase in K+ permeability secondary to a rise in cytoplasmic Ca2+ concentration."( Effects of cetiedil on monovalent cation permeability in the erythrocyte: an explanation for the efficacy of cetiedil in the treatment of sickle cell anemia.
Berkowitz, LR; Orringer, EP, 1982
)
1.38
"Cetiedil has been reported to relieve painful crises in sickle cell anemia and to have antisickling properties in vitro. "( Effect of cetiedil, an in vitro antisickling agent, on erythrocyte membrane cation permeability.
Berkowitz, LR; Orringer, EP, 1981
)
2.11

Actions

Cetiedil was found to inhibit platelet aggregation and thromboxane synthesis induced by thrombin and arachidonic acid. It did lower acetylcholinesterase activity, but it did not directly inhibit this enzyme activity.

ExcerptReferenceRelevance
"Cetiedil did not inhibit calmodulin-stimulated enzyme activities by acting as a calcium chelator, since increasing the concentration of calcium did not reverse the inhibitory effect."( Cetiedil inhibition of calmodulin-stimulated enzyme activity.
Berkowitz, LR; Levine, SN; Orringer, EP, 1984
)
2.43
"Cetiedil's ability to inhibit anion movement was next evaluated, as cetiedil could appear to be blocking K movement when in fact it was preventing the movement of its accompanying anion."( An analysis of the mechanism by which cetiedil inhibits the Gardos phenomenon.
Berkowitz, LR; Orringer, EP, 1984
)
1.26
"Cetiedil, however, did lower acetylcholinesterase activity, but it did not directly inhibit this enzyme activity."( Influence of cetiedil on erythrocyte membrane microviscosity and acetylcholinesterase activity.
Bourdeaux, M; Chauvet, M; Dell'Amico, M; Giannettini, J, 1992
)
1.37
"Cetiedil was found to inhibit platelet aggregation and thromboxane synthesis induced by thrombin and arachidonic acid. "( Effect of cetiedil on platelet aggregation and thromboxane synthesis.
Asakura, T; Tanoue, K; Yamaguchi, A; Yamazaki, H, 1985
)
2.11

Pharmacokinetics

ExcerptReferenceRelevance
" With the use of a sensitive GC/MS assay, the pharmacokinetic profile of cetiedil was studied in normal men and in men with sickle cell anemia who were not in crisis at the time of study."( A single-dose pharmacokinetic study of the antisickling agent cetiedil.
Berkowitz, LR; Cross, RE; Ng, KT; Orringer, EP; Phillips, JC; Powell, JR; Reed, J; Rogers, JF; Wojcieszyn, O, 1986
)
0.74

Dosage Studied

Dose-response studies showed that thyroid hormone stimulation of Ca2+-ATPase activity in vitro was significantly inhibited by as little as 2 x 10(-5) M bepridil and cetiedil. Additional clinical studies will be necessary before an optimal dosing regimen can be established.

ExcerptRelevanceReference
" Dose-response studies showed that thyroid hormone stimulation of Ca2+-ATPase activity in vitro was significantly inhibited by as little as 2 x 10(-5) M bepridil and cetiedil."( Bepridil and cetiedil reversibly inhibit thyroid hormone stimulation in vitro of human red cell Ca2+-ATPase activity.
Blas, SD; Davis, FB; Davis, PJ; Dube, MP, 1987
)
0.84
" Because the cetiedil plasma levels achieved during this in vivo study are well below concentrations that exhibit antisickling activity in vitro, additional clinical studies will be necessary before an optimal dosing regimen can be established."( A single-dose pharmacokinetic study of the antisickling agent cetiedil.
Berkowitz, LR; Cross, RE; Ng, KT; Orringer, EP; Phillips, JC; Powell, JR; Reed, J; Rogers, JF; Wojcieszyn, O, 1986
)
0.88
" The assigned drug dosage was given as a 30 minute intravenous infusion every 8 hours for 4 consecutive days."( A collaborative, double-blind randomized study of cetiedil citrate in sickle cell crisis.
Benjamin, LJ; Berkowitz, LR; Chillar, RK; Lewkow, LM; Mankad, VN; Orringer, E; Peterson, CM; Prasad, AS, 1986
)
0.52
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
azepanes
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (67)

TimeframeStudies, This Drug (%)All Drugs %
pre-199045 (67.16)18.7374
1990's18 (26.87)18.2507
2000's4 (5.97)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (4.23%)5.53%
Reviews5 (7.04%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other63 (88.73%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]